A Phase 2 Multicenter, Randomized, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of CBT-004 Ophthalmic Emulsion in Patients With Vascularized Pinguecula
Latest Information Update: 05 Feb 2024
At a glance
- Drugs CBT-004 (Primary)
- Indications Pinguecula
- Focus Adverse reactions
- Sponsors Cloudbreak therapeutics
- 25 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Oct 2025.
- 25 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Aug 2025.
- 25 Jan 2024 Status changed from not yet recruiting to recruiting.